Business Wire

Veracode Report Finds 63% of Financial Services Firms Carry Critical Security Debt, Heightening Supply Chain Risk

29.10.2025 13:50:00 EET | Business Wire | Press release

Share

Veracode, the global leader in application risk management, today released its 2025 State of Software Security (SoSS) Snapshot for the Financial Services Sector. The analysis reveals nearly two-thirds (63 percent) of banking, financial services, and insurance (BFSI) organizations harbor critical security debt—high-severity flaws left unfixed for longer than a year—a rate of 13 percentage points higher than the cross-industry average.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251029207424/en/

Fig. 1: Financial service sector flaw remediation timeline based on survival analysis

"Trust is everything in financial services, yet our data reveals a silent, growing risk for the sector created by unresolved security debt," said Chris Wysopal, Co-founder & Chief Security Evangelist at Veracode. "With AI-driven attacks surging and compliance requirements tightening, finance leaders must prioritize strategic risk reduction, starting with targeted remediation of critical software flaws.”

Veracode researchers report 77 percent of financial services organizations accrue some level of security debt. With an average flaw half-life of 276 days—the time it takes to remediate 50 percent of all vulnerabilities—it takes the sector nearly a month longer to fix security issues than other industries. Despite modest gains in reducing high-severity flaws, progress has stalled as older, larger applications in the sector continue to accumulate unresolved security risks.

Open-Source Dependency Amplifies Exposure

The report found the supply chain remains a major source of risk. While third-party code represents just 17 percent of total security debt, it accounts for more than 82 percent of critical security debt at financial firms. With open-source flaws requiring 50 percent more time to remediate than first-party code, organizations face mounting exposure amid escalating regulatory pressure. Proactively assessing open-source libraries and avoiding components with known flaws significantly reduces long-term exposure and risk across applications.

Leaders vs. Laggards: Benchmarking AppSec Maturity

The report benchmarks top-performing BFSI enterprises against lower-performing organizations. Industry leaders remediate over 9 percent of open flaws monthly and limit security debt to less than 26 percent of applications, while laggards have debt in 85 percent or more of their applications and stretch fix cycles beyond a year. The gap underscores the importance of continuous code analysis, rapid remediation, and contextual risk-based prioritization with modern, AI-powered tools.

Wysopal concluded, "This report gives finance leaders the data they need to benchmark progress and target resources more effectively. By understanding where critical open-source and legacy risks are concentrated, organizations can move beyond simply finding flaws to strategically fixing the most critical issues, enabling them to protect their customers while innovating securely and with confidence.”

The Veracode 2025 State of Software Financial Services Snapshot is available to read on the Veracode website.

About the State of Software Security Report

The Veracode State of Software Security 2025 is the 15th volume of the report. It analyzed data from companies of all sizes, commercial software suppliers, software outsourcers, and open-source projects. The report contains findings about applications that were subjected to static analysis, dynamic analysis, software composition analysis, and/or manual penetration testing through Veracode’s cloud-based platform. Specifically, the data comes from:

  • 1.3M unique applications with 126.4M raw findings
  • 107.4M findings identified via SAST scans
  • 3.9M findings identified via DAST scans
  • 15M findings identified via Software Composition Analysis

About Veracode

Veracode is a global leader in Application Risk Management for the AI era. Powered by trillions of lines of code scans and a proprietary AI-assisted remediation engine, the Veracode platform is trusted by organizations worldwide to build and maintain secure software from code creation to cloud deployment. Thousands of the world’s leading development and security teams use Veracode every second of every day to get accurate, actionable visibility of exploitable risk, achieve real-time vulnerability remediation, and reduce their security debt at scale.

Veracode is a multi-award-winning company offering capabilities to secure the entire software development life cycle, including Veracode Fix, Static Analysis, Dynamic Analysis, Software Composition Analysis, Container Security, Application Security Posture Management, Malicious Package Detection, and Penetration Testing.

Learn more at www.veracode.com, on the Veracode blog, and on LinkedIn and X.

View source version on businesswire.com: https://www.businesswire.com/news/home/20251029207424/en/

Contacts

Media:
Katy Gwilliam
Head of Global Communications, Veracode
kgwilliam@veracode.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

www.businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 20:52:00 EEST | Press release

International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he has served as pro bono counsel to five Nobel Peace Prize laureates. The New York Times has referred to him as "The Extractor" for his work freeing political prisoners worldwide. Genser's decision to support Yim Leak's team comes as the businessman faces an asset freeze exceeding 20 billion baht (more than U

Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 18:38:00 EEST | Press release

Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co

Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli ® (Relacorilant)18.9.2026 15:00:00 EEST | Press release

Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth

Enhertu ® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 15:00:00 EEST | Press release

Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at the 2025 European Society for Medical Oncology (#ESMO25) Congress and subsequently published in The New England Journal of Medicine. The recommendation will now be reviewed by the European Commission, which has the authority to grant marketing authorizations for medicines in the EU. In DES

CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca ® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 13:58:00 EEST | Press release

Alfasigma S.p.A, a global pharmaceutical company with a focus on innovation in rare disease and specialty care in areas where there is significant unmet patient need, today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion for Jyseleca® (filgotinib), an oral, once-daily JAK1 preferential inhibitor, for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy. Following this positive opinion, the application is now referred to the European Commission (EC) for final action. The EC’s decision is expected in the next weeks. “At present, half of people living with axSpA fail to adequately respond to treatment, leaving them with years of preventable struggle with persistent pain and other impactful symptoms,” said Daniele D'Ambrosio, Chief Development Officer, Alfasigma. “This

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye